Literature DB >> 1284150

Effect of gallopamil on cardiac sarcoplasmic reticulum.

R Zucchi1, S Ronca-Testoni, U Limbruno, G Yu, P Galbani, G Ronca, M Mariani.   

Abstract

We investigated the effect of gallopamil on cardiac sarcoplasmic reticulum (SR) function. Heavy SR was prepared from bovine ventricular muscle. Oxalate-supported calcium uptake was stimulated by gallopamil at concentrations ranging from 10 to 300 nM, whereas higher concentrations were ineffective. Peak stimulation averaged 25-30% of control calcium uptake and was observed at free calcium concentrations ranging from 1 to 6 microM. Calcium uptake is actually the difference between active calcium transport by SR calcium-adenosine triphosphate (calcium-ATPase), and passive efflux through SR calcium-release channels. In the presence of 300 microM of ryanodine, a blocker of SR channels, calcium uptake increased by 43% under control conditions, but not further stimulation was produced by gallopamil. SR calcium-ATPase was not affected by gallopamil. Similar results were obtained when oxalate-supported calcium uptake was determined with use of unfractionated homogenate obtained from rat hearts. We conclude that gallopamil acts on SR calcium-release channels and reduces the probability of channel opening and/or channel conductivity. The dose-response curve is bell shaped, and the maximum effect, which corresponds to 65% of the maximum effect of ryanodine, is achieved at therapeutic concentrations. Such action might contribute to the beneficial effect of gallopamil in the treatment of myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1284150

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Interaction between gallopamil and cardiac ryanodine receptors.

Authors:  R Zucchi; S Ronca-Testoni; G Yu; P Galbani; G Ronca; M Mariani
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 2.  How do calcium antagonists differ in clinical practice?

Authors:  R Ferrari; F Cucchini; R Bolognesi; T Bachetti; A Boraso; P Bernocchi; G Gaia; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

Review 3.  Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.